Author Affiliation: Winship Cancer Institute, Emory University, Atlanta, Ga.
Considerable progress has been made in the last 20 years in improving
outcomes for patients with breast cancer because of earlier detection and
application of more effective therapies. The use of tamoxifen reduces the
risk of recurrence and improves survival in patients with early stage hormone
receptor–positive breast cancer.1 Recent
evidence suggests that adjuvant use of aromatase inhibitors may further add
to the benefits seen with tamoxifen.2- 4 Likewise,
the use of adjuvant chemotherapy has been demonstrated to reduce recurrence
and mortality in patients with early stage breast cancer, particularly in
younger patients and in those with tumors that do not express hormone receptors.5 Nonetheless, many patients would remain free of cancer
following local therapy (surgery with or without radiotherapy) with no adjuvant
systemic hormonal or chemotherapy. Much research is currently focused on tailoring
the use of adjuvant systemic therapies and on identifying patients with tumor
characteristics associated with a favorable prognosis.
O'Regan RM. Do Tumors Detected by Mammography Screening Have a Favorable Prognosis?. JAMA. 2004;292(9):1062-1063. doi:10.1001/jama.292.9.1062